Guido Kroemer Selected Research

Calreticulin

1/2022	Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.
12/2021	Subversion of calreticulin exposure as a strategy of immune escape.
1/2021	Calreticulin Exposure in Mitotic Catastrophe.
1/2021	Calreticulin and cancer.
12/2020	Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
1/2020	Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
1/2020	Quantitation of calreticulin exposure associated with immunogenic cell death.
1/2020	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death.
1/2020	Quantitative determination of phagocytosis by bone marrow-derived dendritic cells via imaging flow cytometry.
11/2019	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guido Kroemer Research Topics

Disease

440	Neoplasms (Cancer) 10/2022 - 01/2002
35	Necrosis 01/2022 - 03/2004
30	Breast Neoplasms (Breast Cancer) 03/2022 - 09/2007
30	Carcinogenesis 01/2022 - 11/2003
27	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 08/2004
26	Melanoma (Melanoma, Malignant) 01/2022 - 04/2006
24	Obesity 11/2021 - 07/2010
24	Carcinoma (Carcinomatosis) 01/2021 - 01/2002
23	Starvation 01/2022 - 11/2005
21	Inflammation (Inflammations) 05/2022 - 10/2011
21	Infections 01/2022 - 03/2002
18	Tetraploidy 11/2021 - 06/2006
18	Cystic Fibrosis (Mucoviscidosis) 12/2020 - 09/2013
17	Neoplasm Metastasis (Metastasis) 05/2021 - 08/2011
16	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2002
14	Hypoxia (Hypoxemia) 01/2021 - 07/2003
11	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 02/2006
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 02/2008
10	Polyploidy 11/2017 - 09/2004
9	COVID-19 01/2022 - 01/2020
9	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 05/2012
8	Colonic Neoplasms (Colon Cancer) 01/2022 - 04/2004
8	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 12/2016
8	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2020 - 01/2007
8	Ischemia 01/2020 - 07/2003
7	Mitochondrial Diseases (Mitochondrial Disease) 03/2022 - 01/2002
7	Pancreatic Neoplasms (Pancreatic Cancer) 11/2021 - 09/2012
7	Residual Neoplasm 01/2021 - 10/2007
6	Celiac Disease (Celiac Sprue) 12/2019 - 01/2019
5	Heart Failure 10/2022 - 12/2005
5	Weight Gain 04/2022 - 01/2017
5	Multiple Myeloma 03/2022 - 11/2013

Drug/Important Bio-Agent (IBA)

82	Proteins (Proteins, Gene)FDA Link 03/2022 - 05/2003
50	AntigensIBA 01/2022 - 09/2007
41	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 12/2007
37	AnthracyclinesIBA 01/2021 - 03/2007
33	CalreticulinIBA 01/2022 - 01/2007
33	Adenosine Triphosphate (ATP)IBA 01/2022 - 04/2004
32	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2004
29	VaccinesIBA 01/2022 - 09/2003
29	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 04/2006
26	CytokinesIBA 01/2022 - 03/2002
24	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 09/2004
22	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
22	Pharmaceutical PreparationsIBA 01/2022 - 01/2002
21	HMGB1 Protein (HMG1)IBA 01/2022 - 09/2007
19	Biomarkers (Surrogate Marker)IBA 03/2022 - 09/2007
19	Peptides (Polypeptides)IBA 01/2022 - 04/2006
17	InterferonsIBA 01/2022 - 02/2006
17	Phosphotransferases (Kinase)IBA 01/2021 - 01/2008
15	LigandsIBA 12/2021 - 03/2002
15	Monoclonal AntibodiesIBA 01/2021 - 01/2012
15	CaspasesIBA 12/2018 - 01/2002
12	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 09/2007
12	SpermidineIBA 01/2021 - 11/2009
11	5-methoxy-methylindoleacetic acid (DBI)IBA 04/2022 - 01/2019
10	Hormones (Hormone)IBA 01/2022 - 09/2006
10	CarcinogensIBA 01/2021 - 09/2012
10	Therapeutic UsesIBA 10/2020 - 12/2007
10	Apoptosis Inducing FactorIBA 01/2020 - 06/2003
9	Pattern Recognition ReceptorsIBA 01/2022 - 08/2009
9	AntibodiesIBA 01/2022 - 08/2011
9	LipidsIBA 11/2021 - 01/2008
9	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 08/2013
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 03/2012
8	EnzymesIBA 05/2022 - 11/2011
8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 05/2004
8	PolyaminesIBA 11/2021 - 11/2009
8	InterleukinsIBA 01/2020 - 03/2010
8	InflammasomesIBA 01/2019 - 10/2009
8	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2019 - 03/2012
8	Toll-Like Receptor AgonistsIBA 01/2018 - 08/2012
8	Toll-Like Receptor 4IBA 02/2016 - 09/2007
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2014 - 07/2007
7	Transcription Factors (Transcription Factor)IBA 03/2022 - 03/2004
7	Messenger RNA (mRNA)IBA 01/2022 - 01/2017
7	Histones (Histone)IBA 01/2021 - 06/2008
7	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021 - 01/2015
7	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 04/2004
7	Sirolimus (Rapamycin)FDA Link 10/2019 - 01/2006
7	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 07/2019 - 12/2016
7	ErbB Receptors (EGF Receptor)IBA 12/2014 - 07/2007
6	Fatty Acids (Saturated Fatty Acids)IBA 10/2022 - 07/2010
6	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 11/2007
6	Interferon Type IIBA 01/2022 - 11/2014
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 02/2007
6	ChromatinIBA 01/2022 - 09/2004
6	CrizotinibIBA 01/2021 - 01/2019
6	Diazepam Binding InhibitorIBA 01/2021 - 10/2019
6	Tyrosine Kinase InhibitorsIBA 01/2020 - 07/2007
6	Glutens (Glutelin)IBA 12/2019 - 01/2019
6	GliadinIBA 12/2019 - 01/2019
6	Purinergic Receptors (Receptors, Purine)IBA 01/2019 - 10/2009

Therapy/Procedure

161	Therapeutics 03/2022 - 01/2002
96	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
69	Immunotherapy 01/2022 - 01/2008
31	Radiotherapy 01/2021 - 12/2006
9	Neoadjuvant Therapy 01/2021 - 09/2011
8	Caloric Restriction 03/2021 - 01/2010
6	Adjuvant Chemotherapy 06/2016 - 05/2012